|1.||Pezzuto, John M: 3 articles (08/2004 - 02/2004)|
|2.||Cuendet, Muriel: 3 articles (08/2004 - 02/2004)|
|3.||De Blanco, Esperanza J Carcache: 1 article (09/2010)|
|4.||Lau, Edward K: 1 article (09/2010)|
|5.||Kim, Jeong-Ah: 1 article (09/2010)|
|6.||Pan, Li: 1 article (09/2010)|
|7.||Carrier, Marilyn: 1 article (01/2009)|
|8.||Rawe, Svea: 1 article (01/2009)|
|9.||Robert, Francis: 1 article (01/2009)|
|10.||Pelletier, Jerry: 1 article (01/2009)|
|1.||Hematologic Neoplasms (Hematological Malignancy)
02/01/2004 - "Responses of this type suggest bruceantin should be reinvestigated for clinical efficacy against hematological malignancies."
02/01/2004 - "These results suggest that bruceantin should be reinvestigated for clinical efficacy against multiple myeloma and other hematological malignancies."
11/01/1979 - "Bruceantin was administered to 33 patients with advanced solid tumors or hematologic neoplasms. "
11/01/1979 - "A phase I clinical study of bruceantin was conducted in 66 patients with various types of advanced solid tumors to evaluate its toxicity and efficacy. "
02/01/2004 - "Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin (37%) as compared with the control tumors (14%). "
02/01/2004 - "Bruceantin treatment (2.5-5 mg/kg) resulted in a significant regression of tumors without overt toxicity. "
02/01/2004 - "Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin. "
01/01/1982 - "During the phase I clinical trial of a new antitumor agent, bruceantin, the pharmacology was studied in 18 cancer patients. "
|4.||Melanoma (Melanoma, Malignant)
01/01/1983 - "The Eastern Cooperative Oncology Group (ECOG) conducted a Phase II trial of Bruceantin in malignant melanoma. "
01/01/1983 - "A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma."
01/01/1983 - "Bruceantin has only limited activity against malignant melanoma and is unlikely to contribute to systemic therapy of this disease, either as a single agent or in combinations of cytotoxic drugs."
08/01/1982 - "Phase II trial of bruceantin in metastatic breast carcinoma."
|2.||Eukaryotic Initiation Factor-4E
|7.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)